Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol

INTRODUCTION: Management of neuropathic cancer pain (NCP) refractory to regular opioids remains an important challenge. The efficacy of pregabalin for NCP except chemotherapy-induced peripheral neuropathy (CIPN) has already been confirmed in two randomised controlled trials (RCTs) compared with plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiromichi, Clark, Katherine, Fazekas, Belinda, Oyamada, Shunsuke, Brown, Linda, Ishiki, Hiroto, Matsuda, Yoshinobu, Hasuo, Hideaki, Ariyoshi, Keisuke, Lee, Jessica, Le, Brian, Allcroft, Peter, Kochovska, Slavica, Fujiwara, Noriko, Miyaji, Tempei, Lovell, Melanie, Agar, Meera, Yamaguchi, Takuhiro, Satomi, Eriko, Iwase, Satoru, Phillips, Jane, Koyama, Atsuko, Currow, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Palliative Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823224/
https://www.ncbi.nlm.nih.gov/pubmed/35131817
http://dx.doi.org/10.1136/bmjopen-2021-050182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823224/
https://www.ncbi.nlm.nih.gov/pubmed/35131817
http://dx.doi.org/10.1136/bmjopen-2021-050182

Ejemplares similares